Genflow Biosciences Stock Price, News & Analysis

Genflow Biosciences Plc (GENFF) is a biotechnology company that focuses on longevity research and the development of gene therapies aimed at decelerating the aging process and preventing age-related diseases. The company is headquartered in the United Kingdom and has research and development facilities in Belgium. Genflow’s shares trade on the London Stock Exchange under the symbol GENF and on the OTCQB market under the symbol GENFF.

Founded in 2020, Genflow describes itself as a biotechnology company pioneering gene therapies to slow biological aging. According to the company’s public statements, its goal is to promote longer and healthier lives while reducing the financial, emotional, and social impacts associated with an aging global population. Genflow positions its work within the field of longevity therapeutics, with a particular focus on the SIRT6 gene and its variants.

Core scientific focus and technology platform

Genflow’s lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene. The company reports that this variant has yielded promising preclinical results. SIRT6 is described in Genflow’s communications as a gene sourced from human centenarians that plays a role in DNA repair, metabolic regulation, and resistance to age-related decline. By using this centenarian SIRT6 variant in gene therapy constructs, Genflow aims to build a therapeutic platform targeting aging mechanisms.

The company highlights a longevity gene therapy platform centered on SIRT6-based technologies. It has reported progress in building an intellectual property portfolio around SIRT6 variants, including European patent activity. Genflow notes that its European patent applications and publications cover SIRT6 variants for healthy aging and for metabolic and age-related disorders.

Research programs and clinical development

Genflow’s public disclosures describe several programs built around its SIRT6-based gene therapies. The company’s 12‑month proof‑of‑concept clinical trial in aged dogs is a key element of its development strategy. This trial evaluates a SIRT6‑centenarian gene therapy in elderly dogs and is intended to generate data on safety, tolerability, and potential effects on age‑related decline.

In its updates, Genflow reports that the dog aging study involves beagles aged 10 years and older in a randomized, controlled trial. The company has stated that its proprietary centenarian SIRT6 gene therapy has been administered in different modalities and that repeat administration has shown an excellent safety and tolerability profile, with no ill or adverse effects observed in the reported dosing phases. The trial is designed as a blinded clinical study, with follow‑up periods and planned efficacy assessments based on blood analyses, muscle biopsies, and biomarkers related to sarcopenia, healthspan, and lifespan‑associated measures.

Beyond animal health, Genflow also describes human‑focused longevity programs. The company states that it is developing a clinical trial to explore the potential benefits of GF‑1002 in treating MASH (Metabolic Dysfunction‑Associated Steatohepatitis), which it characterizes as a prevalent chronic liver disease for which there are no effective treatments. In its communications, Genflow links this MASH program to its broader strategy of applying SIRT6 gene variants to metabolic and age‑related disorders.

Animal health and longevity applications

Genflow has emphasized an animal health program as part of its longevity strategy. The company describes its dog aging study (sometimes referred to as GF‑1004) as a proof‑of‑concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6‑centenarian gene therapy for age‑related decline in elderly dogs. According to Genflow, this program is intended to demonstrate the applicability of its gene therapy platform beyond human health.

In its public updates, Genflow notes that the SIRT6 gene therapy has been administered multiple times in the dog trial, with safety and tolerability reported as strong. The company also indicates that it views the global animal health market as a significant opportunity for longevity‑based treatments aimed at improving healthspan, vitality, and lifespan in companion animals and potentially livestock. Genflow has mentioned engagement with animal health companies and potential early‑stage licensing discussions related to this program.

Intellectual property and patent activity

Genflow’s strategy includes building an intellectual property portfolio around its SIRT6‑based technologies. The company has reported that the European Patent Office recognized the patentability of claims in a Euro‑PCT application related to its SIRT6 variant patent, with publication in the European Patent Office Bulletin. This publication confers provisional protection under Article 67(3) of the European Patent Convention, subject to subsequent steps such as bringing the description into compliance with the claims and national validation.

In addition, Genflow has announced the publication of a second European patent application titled “SIRT6 Variant for NASH” in the European Patent Bulletin. The company describes this as part of a comprehensive patent strategy to strengthen protection for SIRT6 gene variant technologies and to expand their therapeutic reach across metabolic and age‑related disorders, including NASH (non‑alcoholic steatohepatitis). Genflow states that these filings together establish a European patent framework supporting its therapeutic platform and planned clinical programs.

Corporate profile and capital markets

Genflow Biosciences Plc is a UK issuer and has described itself as the only publicly listed longevity company in Europe in its announcements. The company’s ordinary shares are listed on the main market for listed securities of the London Stock Exchange and are also quoted on the OTCQB market in the United States under the symbol GENFF. Genflow has issued regulatory announcements related to share capital, voting rights, and holdings in the company, reflecting its status as a listed issuer subject to disclosure rules.

The company has reported fundraisings through the allotment of new ordinary shares and the issuance of warrants, as well as notifications of major shareholdings under UK disclosure regulations. These announcements describe transactions in ordinary shares, the resulting total number of voting rights, and the use of exemptions under the UK Prospectus Regulation for specific subscriptions.

Sector and industry classification

Within industry classifications, Genflow Biosciences Plc operates in biotechnology research and development. The provided classification places the company in the sector of Professional, Scientific, and Technical Services, with a specific focus on research and development in biotechnology. Its activities center on gene therapy research, preclinical and clinical studies, and intellectual property development in the field of aging and longevity.

Position in the longevity field

In its public communications, Genflow describes itself as an emerging leader in longevity research and as the only publicly listed longevity company in Europe. The company’s narrative emphasizes a focus on therapeutic solutions for the prevention of age‑related diseases, with SIRT6‑based gene therapies as the core of its scientific and development strategy. Through its combination of animal health studies, planned human‑focused programs, and patent activity, Genflow presents a profile centered on genetic approaches to extending healthspan.

Key points for GENFF investors and observers

• Genflow Biosciences Plc is a biotechnology company focused on longevity and gene therapies, headquartered in the UK with R&D facilities in Belgium.
• The company was founded in 2020 and is listed on the London Stock Exchange (GENF) and OTCQB (GENFF).
• Its lead compound, GF‑1002, delivers a centenarian variant of the SIRT6 gene and has shown promising preclinical results according to company statements.
• Genflow is running a 12‑month proof‑of‑concept clinical trial of SIRT6‑centenarian gene therapy in aged dogs, with reported strong safety and tolerability in dosing phases.
• The company is planning a clinical trial to explore GF‑1002 in MASH and is developing a broader SIRT6‑based therapeutic platform for metabolic and age‑related disorders.
• Genflow is building an intellectual property portfolio around SIRT6 variants, including European patent publications covering healthy aging and NASH applications.
• As a listed issuer, Genflow regularly reports on share capital changes, voting rights, and major holdings under UK regulatory requirements.